CliffBio
small molecule

KYNAMRO

MIPOMERSEN SODIUM

Loss of exclusivityJanuary 2027latest FDA-listed patent expiry
CompanyKastle →View the full company profile on CliffBio

Drug detail

Brand nameKYNAMRO
Active ingredientMIPOMERSEN SODIUM
Strength200MG/ML (200MG/ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusDISCN

Listed patents

PatentExpiresType
7511131January 2027substance

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

KYNAMRO patent cliff — loss of exclusivity January 2027 | CliffBio